Article
PRDM16 expression is an independent prognostic factor in AML with the double-mutant NPM1/FLT3-ITD genotype.
Annals of hematology - 22 Jan 2026
Stasik Sebastian, Eckardt Jan-Niklas, Röllig Christoph, Baldus Claudia D, Serve Hubert, Müller-Tidow Carsten, Schäfer-Eckart Kerstin, Kaufmann Martin, Krause Stefan W, Hänel Mathias, Neubauer Andreas, Ehninger Gerhard, Platzbecker Uwe, Bornhäuser Martin, Schetelig Johannes, Middeke Jan M, Thiede Christian
Abstract excerpt
PRDM16 (PR Domain Containing 16) is a transcription factor that plays a critical role in hematopoietic stem cell maintenance. In acute myeloid leukemia (AML), PRDM16 overexpression is linked to specific cytogenetic risk groups and poor prognosis. However, in NPM1-mutated AMLs, PRDM16 expression varies widely, with no consensus on its prognostic significance. To understand molecular and clinical associations of...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
